Pharmaceuticals, Biotechnology & Life Sciences

Roivant Sciences sees board shares boost and BlackRock’s stake over 8%—signaling tighter governance, stronger investor alignment, and growth‑ready biotech strategy.

Explore Eli Lilly’s 2027 Global Markets overhaul and legal win against Novo Nordisk—how the restructuring boosts global reach, margins, and obesity‑treatment dominance while navigating regulatory risks.

Discover why Sartorius AG’s bioprocessing tech powers next‑gen biologics, fuels investor value, and keeps its shares steady amid mid‑cap TecDAX trends.

Explore how Bayer’s new MustGrow partnership and EU biopesticide approvals could reshape the agribusiness market, boosting sustainable crop solutions.

Explore how Danaher’s product innovation, advanced manufacturing and supply‑chain partnerships boost financial strength, investor confidence and healthcare delivery.

Biogen Inc’s upcoming Q4 results reveal a modest revenue rise but shrinking EPS amid patent cliffs and market‑access pressures, urging investors to watch its pipeline and M&A moves.

IQVIA reports a strong Q4 2026 earnings surge, with EPS of $3.26 and revenue up 6.5%, driving a 2026 outlook of $12.94 EPS and $17.4 billion revenue driven by data‑science‑powered clinical research and precision therapeutics.

Gilead Sciences balances a strong financial base with a dual oncology‑and‑NASH pipeline, using AI‑driven precision medicine and value‑based deals to capture emerging markets.

Amgen strengthens governance with ex‑Yum! CEO David Gibbs, while its oncology, rare‑disease, and cardiovascular pipeline shows breakthrough trial results and FDA progress.

Japanese equities rebound, tech and banks surge; Daiichi Sankyo drops market‑wide. Meanwhile NYU‑led trial shows sacituzumab tirumotecan boosts survival in endometrial cancer.